Latest ArticlesEN-USMon, 23 Jan 2017 01:14:40 -0500729789
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3KBRsNDd-6E/bristol-myers-extends-deal-with-five-prime-therapeutics-cm729789
Bristol-Myers Extends Deal with Five Prime TherapeuticsBristol Myers Squibb Company BMY has exercised its option to extend the term of its existing research collaboration agreement with Five Prime Therapeutics Inc FPRX for the discovery development and commercialization of immuno oncology therapies focused on targets in three undisclosed<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/3KBRsNDd-6E" height="1" width="1" alt=""/>Thu, 05 Jan 2017 14:41:07 Z2017-01-05T14:41:07Zhttp://www.nasdaq.com/article/bristol-myers-extends-deal-with-five-prime-therapeutics-cm72978920170105-00006
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/47JUs3PW9eI/aezs-disappoints-evok-gets-new-lease-of-life-gnmx-calls-for-attention-20170105-00006
AEZS Disappoints, EVOK Gets New Lease Of Life, GNMX Calls For AttentionAEZS Disappoints, EVOK Gets New Lease Of Life, GNMX Calls For Attention<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/47JUs3PW9eI" height="1" width="1" alt=""/>Thu, 05 Jan 2017 00:44:00 Z2017-01-05T00:44:00Zhttp://www.nasdaq.com/article/aezs-disappoints-evok-gets-new-lease-of-life-gnmx-calls-for-attention-20170105-00006701870
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ewhF_kVCsv0/commit-to-buy-five-prime-therapeutics-at-40-earn-134-annualized-using-options-cm701870
Commit To Buy Five Prime Therapeutics At $40, Earn 13.4% Annualized Using OptionsInvestors considering a purchase of Five Prime Therapeutics Inc Symbol FPRX stock but tentative about paying the going market price of 49 36 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/ewhF_kVCsv0" height="1" width="1" alt=""/>Tue, 01 Nov 2016 17:14:43 Z2016-11-01T17:14:43Zhttp://www.nasdaq.com/article/commit-to-buy-five-prime-therapeutics-at-40-earn-134-annualized-using-options-cm701870688278
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/W6BSRM1xQNg/stock-picks-for-quant-strategies-cm688278
Stock Picks for Quant StrategiesThere s an increasing amount of buzz on the street about the folks behind the curtain who build complex algorithms and mathematical models intended to detect and exploit market inefficiencies As hedge funds continue to lose clients disenchanted with lagging performance quant<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/W6BSRM1xQNg" height="1" width="1" alt=""/>Tue, 04 Oct 2016 20:20:52 Z2016-10-04T20:20:52Zhttp://www.nasdaq.com/article/stock-picks-for-quant-strategies-cm688278660086
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6G3Ikt4Qw2U/5-mid-cap-stocks-with-low-enterprise-multiples-cm660086
5 Mid-Cap Stocks With Low Enterprise MultiplesThis article appeared first onThe Stock Market Blueprint Blog. In this edition of Watchlist Wednesday, we highlight five mid cap stocks with low enterprise multiples, as displayed on the Enterprise Multiple screen . The enterprise multiple is a price<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/6G3Ikt4Qw2U" height="1" width="1" alt=""/>Thu, 04 Aug 2016 02:52:06 Z2016-08-04T02:52:06Zhttp://www.nasdaq.com/article/5-mid-cap-stocks-with-low-enterprise-multiples-cm660086658939
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RhOBbZ8Uc7Q/commit-to-purchase-five-prime-therapeutics-at-35-earn-97-annualized-using-options-cm658939
Commit To Purchase Five Prime Therapeutics At $35, Earn 9.7% Annualized Using OptionsInvestors considering a purchase of Five Prime Therapeutics, Inc (Symbol FPRX) stock, but cautious about paying the going market price of $50.00 share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/RhOBbZ8Uc7Q" height="1" width="1" alt=""/>Tue, 02 Aug 2016 16:53:13 Z2016-08-02T16:53:13Zhttp://www.nasdaq.com/article/commit-to-purchase-five-prime-therapeutics-at-35-earn-97-annualized-using-options-cm658939651096
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jm4xow0gmDk/fprx-crosses-above-average-analyst-target-cm651096
FPRX Crosses Above Average Analyst TargetIn recent trading, shares of Five Prime Therapeutics, Inc (Symbol FPRX) have crossed above the average analyst 12 month target price of $45.33, changing hands for $45.72 share. When a stock reaches the target an analyst has set, the<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/jm4xow0gmDk" height="1" width="1" alt=""/>Tue, 19 Jul 2016 14:08:53 Z2016-07-19T14:08:53Zhttp://www.nasdaq.com/article/fprx-crosses-above-average-analyst-target-cm651096615525
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-OaV6MQX5m0/commit-to-purchase-five-prime-therapeutics-at-40-earn-228-annualized-using-options-cm615525
Commit To Purchase Five Prime Therapeutics At $40, Earn 22.8% Annualized Using OptionsInvestors eyeing a purchase of Five Prime Therapeutics, Inc (Symbol FPRX) shares, but cautious about paying the going market price of $46.27 share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/-OaV6MQX5m0" height="1" width="1" alt=""/>Tue, 03 May 2016 17:44:22 Z2016-05-03T17:44:22Zhttp://www.nasdaq.com/article/commit-to-purchase-five-prime-therapeutics-at-40-earn-228-annualized-using-options-cm615525607987
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QQaqooAs_ZI/top-4-sales-growth-stocks-cm607987
Top 4 Sales Growth StocksInvestors often overlook sales growth while picking stocks, as a company's stock price is typically sensitive to its earnings momentum. However, earnings are quite vulnerable in the sense that books can be easily cooked and inflated. That's why sales<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/QQaqooAs_ZI" height="1" width="1" alt=""/>Tue, 19 Apr 2016 06:04:37 Z2016-04-19T06:04:37Zhttp://www.nasdaq.com/article/top-4-sales-growth-stocks-cm607987605153
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-xvxCQeC6ck/looking-for-a-top-momentum-stock-3-reasons-why-five-prime-therapeutics-fprx-is-a-great-choice-cm605153
Looking for a Top Momentum Stock? 3 Reasons Why Five Prime Therapeutics (FPRX) is a Great ChoiceMany investors like to look for momentum in stocks, but this can be very tough to define. There is great debate regarding which metrics are the best to focus on in this regard, and which are not really quality<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/-xvxCQeC6ck" height="1" width="1" alt=""/>Tue, 12 Apr 2016 15:08:21 Z2016-04-12T15:08:21Zhttp://www.nasdaq.com/article/looking-for-a-top-momentum-stock-3-reasons-why-five-prime-therapeutics-fprx-is-a-great-choice-cm605153603668
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Vl7ZH9scMxo/can-the-rally-in-five-prime-therapeutics-fprx-shares-continue-cm603668
Can the Rally in Five Prime Therapeutics (FPRX) Shares Continue?Five Prime Therapeutics Inc FPRX has been on the move lately as the stock has risen by 38.2% in the past four weeks, and it is currently trading well above its 20 Day SMA. This is a pretty solid<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/Vl7ZH9scMxo" height="1" width="1" alt=""/>Fri, 08 Apr 2016 15:07:31 Z2016-04-08T15:07:31Zhttp://www.nasdaq.com/article/can-the-rally-in-five-prime-therapeutics-fprx-shares-continue-cm603668599354
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NO09aDAOijM/five-prime-therapeutics-fprx-looks-good-stock-adds-5-cm599354
Five Prime Therapeutics (FPRX) Looks Good: Stock Adds 5%Five Prime Therapeutics, Inc.FPRX was a big mover last session, as the company saw its shares rise just over 5% on the day. The move came on solid volume too with far more shares changing hands than in a<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/NO09aDAOijM" height="1" width="1" alt=""/>Wed, 30 Mar 2016 14:32:49 Z2016-03-30T14:32:49Zhttp://www.nasdaq.com/article/five-prime-therapeutics-fprx-looks-good-stock-adds-5-cm599354591458
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oljbfV9CTyM/after-hours-earnings-report-for-march-10-2016-ulta-fnv-pay-htht-fnsr-vnet-fprx-mmi-iret-prsc-ftd-ff-cm591458
After-Hours Earnings Report for March 10, 2016 : ULTA, FNV, PAY, HTHT, FNSR, VNET, FPRX, MMI, IRET, PRSC, FTD, FFThe following companies are expected to report earnings after hours on 03 10 2016. Visit our Earnings Calendar for a full list of expected earnings releases. Ulta Salon, Cosmetics & Fragrance, Inc. ( ULTA ) is<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/oljbfV9CTyM" height="1" width="1" alt=""/>Thu, 10 Mar 2016 20:05:21 Z2016-03-10T20:05:21Zhttp://www.nasdaq.com/article/after-hours-earnings-report-for-march-10-2016-ulta-fnv-pay-htht-fnsr-vnet-fprx-mmi-iret-prsc-ftd-ff-cm591458581961
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/F38jyuyAlIo/3-biotech-stocks-youll-love-betting-against-fprx-derm-agtc-cm581961
3 Biotech Stocks Youâ€™ll Love Betting Against: FPRX, DERM, AGTCInvestorPlaceInvestorPlace Stock Market News, Stock Advice & Trading Tips After a potent, six year run following the March 2009 equity market lows, the iShares NASDAQ Biotechnology Index (ETF) ( IBB ) has broken down through the major upward trendline<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/F38jyuyAlIo" height="1" width="1" alt=""/>Fri, 19 Feb 2016 13:44:12 Z2016-02-19T13:44:12Zhttp://www.nasdaq.com/article/3-biotech-stocks-youll-love-betting-against-fprx-derm-agtc-cm581961563932
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/by6lGLJlvPM/bristol-myers-bmy-collaborates-with-dual-therapeutics-cm563932
Bristol-Myers (BMY) Collaborates with Dual TherapeuticsBristol Myers SquibbBMY has entered into a strategic collaboration with Dual Therapeutics, LLC to advance small molecule compounds for the treatment of cancer and other diseases. Per the terms of the collaboration agreement, Bristol Myers will get the exclusive,<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/by6lGLJlvPM" height="1" width="1" alt=""/>Mon, 11 Jan 2016 17:16:57 Z2016-01-11T17:16:57Zhttp://www.nasdaq.com/article/bristol-myers-bmy-collaborates-with-dual-therapeutics-cm563932555229
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o7m0vJi1xzk/bristol-myers-ucla-sign-immuno-oncology-collaboration-cm555229
Bristol-Myers & UCLA Sign Immuno-Oncology CollaborationBristol Myers Squibb CompanyBMY announced that it has entered into a collaboration agreement with UCLA under its Immuno Oncology Rare Population Malignancy (I O RPM) research program. The company will conduct a range of early phase studies with the<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/o7m0vJi1xzk" height="1" width="1" alt=""/>Tue, 15 Dec 2015 23:15:49 Z2015-12-15T23:15:49Zhttp://www.nasdaq.com/article/bristol-myers-ucla-sign-immuno-oncology-collaboration-cm555229